Filing Details
- Accession Number:
- 0001479290-23-000083
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-05 21:11:46
- Reporting Period:
- 2023-06-30
- Accepted Time:
- 2023-07-05 21:11:46
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1479290 | Revance Therapeutics Inc. | RVNC | Pharmaceutical Preparations (2834) | 770551645 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1678984 | Tobin Schilke | C/O Revance Therapeutics, Inc. 1222 Demonbreun Street, 20Th Floor Nashville TN 37203 | Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-06-30 | 769 | $15.61 | 81,597 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2023-07-03 | 1,701 | $25.04 | 79,896 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Footnotes
- These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.
Billionaire Hedge Funds
